Burlingame, CA, April 21, 2025 (GLOBE NEWSWIRE) — The global rabies vaccine market size is projected to expand significantly during the forecast period, owing to rising incidence of zoonotic diseases like rabies.
By vaccine type, purified chick embryo cell vaccine (PCECV) segment accounts for a prominent rabies vaccine market share.
Based on end user, hospitals segment is expected to dominate the global rabies vaccine market during the forecast period.
As per Coherent Market Insights’ latest rabies vaccine market analysis, North America will likely retain its dominance during the forecast period. This can be attributed to well-established healthcare infrastructure, growing emphasis on rabies prevention, and presence of leading rabies vaccine manufacturers.
Asia Pacific is expected to emerge as the fastest-growing market during the assessment period, owing to increasing prevalence of rabies.
Request Sample Pages: https://www.coherentmarketinsights.com/insight/request-sample/4005
Increasing Rabies Burden Fueling Market Growth
A new report by Coherent Market Insights outlines significant rabies vaccine market growth factors. One major factor expected to fuel growth of rabies vaccine industry is the increasing incidence of rabies across the world.
Rabies remains a serious public health problem, especially in regions like Asia and Africa. According to the U.S. Centers for Disease Control and Prevention (CDC), rabies kills around 70,000 people worldwide each year.
The spread and mortality rate of rabies can be significantly prevented through vaccination. Thus, a higher incidence of rabies is expected to drive greater demand for rabies vaccines during the forecast period.
High Cost and Limited Accessibility Restraining Market Growth
The future rabies vaccine market outlook looks bright. However, several factors are expected to hinder its growth to some extent. These include high cost of rabies vaccines, limited access in low-resource regions, and low diagnostic rates.
Rabies vaccines used for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) can be expensive, especially for people in …